\-\ Texto\\:\\ \ \(0\)\
\-\ the\\ patient\\ appeared\\ uncomfortable\\ and\\ in\\ significant\\ pain\\.\\ \\ \ \(0\)\
\-\ laboratory\\ values\\ were\\ significant\\ for\\ a\\ urine\\ analysis\\ which\\ demonstrated\\ a\\ large\\ amount\\ of\\ blood\\ with\\ over\\ 100\\ rbcs\\.\\ \\ the\\ ua\\ also\\ showed\\ greater\\ than\\ 300\\ protein\\.\\ \\ the\\ urine\\ culture\\ was\\ negative\\ for\\ growth\\.\\ \\ the\\ patient\\ was\\ afebrile\\ and\\ without\\ an\\ elevated\\ white\\ blood\\ cell\\ count\\.\ \(0\)\
\-\ patient\\ is\\ being\\ treated\\ nonsurgically\\.\\ \\ he\\ is\\ receiving\\ chemotherapy\\ and\\ will\\ be\\ reevaluated\\ with\\ follow\\ up\\ imaging\\.\ \(0\)\
\-\ limited\\ evaluation\\ of\\ the\\ unopacified\\ abdominal\\ viscera\\ demonstrates\\ a\\ right\\ peripelvic\\ cyst\\.\\ \\ no\\ hydronephrosis\\ is\\ appreciated\\.\\ \\ the\\ right\\ ureter\\ is\\ mildly\\ dilated\\,\\ and\\ there\\ is\\ mild\\ perinephric\\ fat\\ stranding\\,\\ right\\ greater\\ than\\ left\\.\\ \\ however\\,\\ no\\ pathologic\\ calcifications\\ are\\ seen\\ within\\ the\\ renal\\ collecting\\ systems\\ or\\ along\\ the\\ course\\ of\\ the\\ bilateral\\ ureters\\.\ \(0\)\
\-\ the\\ posterior\\ bladder\\ wall\\ has\\ a\\ thickened\\ irregular\\ appearance\\.\\ \\ hu\\ measurement\\ was\\ 50\\ consistent\\ with\\ soft\\ tissue\\.\ \(0\)\
\-\ this\\ contour\\ irregularity\\ was\\ further\\ evaluated\\ on\\ a\\ contrast\\ study\\.\\ \\ this\\ showed\\ an\\ extensively\\ thickened\\ posterior\\ bladder\\ wall\\ which\\ did\\ not\\ demonstrate\\ enhancement\\.\\ \\ \ \(0\)\
\-\ the\\ ureterovesicle\\ junction\\ is\\ outlined\\ by\\ contrast\\ on\\ the\\ left\\.\\ \\ contrast\\ was\\ not\\ seen\\ to\\ enter\\ through\\ the\\ right\\ ureterovesicle\\ junction\\.\ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\ \(0\)\
\-\ based\\ on\\ the\\ ct\\ findings\\,\\ transitional\\ cell\\ carcinoma\\ would\\ have\\ to\\ be\\ excluded\\.\\ \\ invasion\\ from\\ prostate\\ cancer\\ would\\ also\\ be\\ a\\ consideration\\.\\ \\ in\\ general\\,\\ focal\\ bladder\\ wall\\ thickening\\ can\\ be\\ seen\\ in\\ acute\\ or\\ chronic\\ inflammation\\ such\\ as\\ cystitis\\,\\ focal\\ muscle\\ hypertrophy\\,\\ squamous\\ cell\\ carcinoma\\,\\ \\ leiomyosarcoma\\,\\ neurofibroma\\,\\ or\\ hemangioma\\.\ \(0\)\
\-\ 39\\-year\\ old\\ male\\ presented\\ to\\ the\\ emergency\\ room\\ with\\ the\\ complaint\\ of\\ gross\\ hematuria\\ and\\ left\\ flank\\ pain\\.\\ \\ a\\ noncontrast\\ ct\\ of\\ the\\ abdomen\\ and\\ pelvis\\ was\\ requested\\ to\\ rule\\ out\\ stones\\.\ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\\ is\\ rare\\,\\ and\\ less\\ than\\ 100\\ cases\\ have\\ been\\ discussed\\ in\\ the\\ literature\\.\\ \\ secondary\\ involvement\\ of\\ the\\ bladder\\ by\\ lymphoma\\ from\\ other\\ sites\\ occurs\\ in\\ approximately\\ 13\\%\\ of\\ patients\\.\\ \\ \ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\\ is\\ thought\\ to\\ typically\\ affect\\ elderly\\ females\\ with\\ a\\ history\\ of\\ chronic\\ cystitis\\.\\ \\ the\\ female\\ to\\ male\\ ration\\ is\\ \\>6\\ to\\ 1\\ with\\ a\\ median\\ age\\ of\\ presentation\\ of\\ 65\\ years\\.\\ \\ this\\ case\\ is\\ certainly\\ unique\\ given\\ that\\ the\\ patient\\ is\\ a\\ young\\ male\\ without\\ a\\ history\\ of\\ chronic\\ bladder\\ infections\\.\\ \\ in\\ addition\\,\\ the\\ lymphoma\\ caused\\ obstruction\\ of\\ the\\ ureterovesicle\\ junction\\ on\\ the\\ right\\.\ \(0\)\
\-\ treatment\\ options\\ include\\ observation\\,\\ chemotherapy\\ and\\ radiation\\ treatment\\.\\ \\ radical\\ surgery\\ has\\ also\\ been\\ performed\\.\\ \\ however\\,\\ according\\ to\\ the\\ literature\\ this\\ is\\ felt\\ to\\ be\\ unnecessary\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bladder\\:\\ 0\\.3365571480770478\ \(0\)\
\-\ the\\:\\ 0\\.3028907821081047\ \(0\)\
\-\ ureterovesicle\\:\\ 0\\.26009685171195196\ \(0\)\
\-\ is\\:\\ 0\\.17816033405066678\ \(0\)\
\-\ lymphoma\\:\\ 0\\.16143703715130356\ \(0\)\
\-\ of\\:\\ 0\\.1591396925396667\ \(0\)\
\-\ junction\\:\\ 0\\.1302589243891004\ \(0\)\
\-\ cystitis\\:\\ 0\\.12781948381054223\ \(0\)\
\-\ to\\:\\ 0\\.12197908138548343\ \(0\)\
\-\ was\\:\\ 0\\.11336333741835893\ \(0\)\
\-\ be\\:\\ 0\\.10996094589630286\ \(0\)\
\-\ literature\\:\\ 0\\.10581899578170276\ \(0\)\
\-\ primary\\:\\ 0\\.10000608705267848\ \(0\)\
\-\ wall\\:\\ 0\\.09893582411926685\ \(0\)\
\-\ urine\\:\\ 0\\.09705579247765073\ \(0\)\
\-\ chronic\\:\\ 0\\.09653848709823373\ \(0\)\
\-\ cell\\:\\ 0\\.09303760358672607\ \(0\)\
\-\ than\\:\\ 0\\.09219602203044623\ \(0\)\
\-\ thickened\\:\\ 0\\.09145962644067246\ \(0\)\
\-\ right\\:\\ 0\\.08986984493858974\ \(0\)\
\-\ and\\:\\ 0\\.08962020206236539\ \(0\)\
\-\ 100\\:\\ 0\\.08895342380304376\ \(0\)\
\-\ nonsurgically\\:\\ 0\\.08284547579215286\ \(0\)\
\-\ peripelvic\\:\\ 0\\.08284547579215286\ \(0\)\
\-\ ration\\:\\ 0\\.08284547579215286\ \(0\)\
\-\ in\\:\\ 0\\.08091913373302095\ \(0\)\
\-\ reevaluated\\:\\ 0\\.0801113919258706\ \(0\)\
\-\ greater\\:\\ 0\\.07988049592323587\ \(0\)\
\-\ contrast\\:\\ 0\\.07902348109812116\ \(0\)\
\-\ unopacified\\:\\ 0\\.0779906717213978\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.07699013169884271\ \(0\)\
\-\ would\\:\\ 0\\.07675327285350107\ \(0\)\
\-\ seen\\:\\ 0\\.07656962012376281\ \(0\)\
\-\ also\\:\\ 0\\.07650121981611042\ \(0\)\
\-\ this\\:\\ 0\\.07451473485942714\ \(0\)\
\-\ uncomfortable\\:\\ 0\\.07352383328109058\ \(0\)\
\-\ male\\:\\ 0\\.07241360811361813\ \(0\)\
\-\ extensively\\:\\ 0\\.072404442368875\ \(0\)\
\-\ showed\\:\\ 0\\.07221985010747448\ \(0\)\
\-\ patient\\:\\ 0\\.07053152606715012\ \(0\)\
\-\ viscera\\:\\ 0\\.06967035850259276\ \(0\)\
\-\ unnecessary\\:\\ 0\\.06754963829811995\ \(0\)\
\-\ outlined\\:\\ 0\\.06693627463631052\ \(0\)\
\-\ enter\\:\\ 0\\.06581688372409496\ \(0\)\
\-\ certainly\\:\\ 0\\.06581688372409496\ \(0\)\
\-\ on\\:\\ 0\\.06549345026786034\ \(0\)\
\-\ rbcs\\:\\ 0\\.06530303760184641\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0648559524218257\ \(0\)\
\-\ focal\\:\\ 0\\.0648559524218257\ \(0\)\
\-\ however\\:\\ 0\\.06417593050030038\ \(0\)\
\-\ with\\:\\ 0\\.0636939113872153\ \(0\)\
\-\ been\\:\\ 0\\.06317062468636062\ \(0\)\
\-\ blood\\:\\ 0\\.0629700896919588\ \(0\)\
\-\ significant\\:\\ 0\\.06260318922392358\ \(0\)\
\-\ measurement\\:\\ 0\\.06232208691592287\ \(0\)\
\-\ 300\\:\\ 0\\.061963408945597154\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.0612842745148009\ \(0\)\
\-\ unique\\:\\ 0\\.060962079653339905\ \(0\)\
\-\ perinephric\\:\\ 0\\.06065045048300425\ \(0\)\
\-\ hu\\:\\ 0\\.06034871599153048\ \(0\)\
\-\ radical\\:\\ 0\\.060056267126773304\ \(0\)\
\-\ ureters\\:\\ 0\\.058968929662103216\ \(0\)\
\-\ transitional\\:\\ 0\\.05846861213742507\ \(0\)\
\-\ without\\:\\ 0\\.057191008796570804\ \(0\)\
\-\ elderly\\:\\ 0\\.057108604874842095\ \(0\)\
\-\ requested\\:\\ 0\\.05669532940736282\ \(0\)\
\-\ or\\:\\ 0\\.05657957843456239\ \(0\)\
\-\ receiving\\:\\ 0\\.056299278843897946\ \(0\)\
\-\ affect\\:\\ 0\\.056107275582584853\ \(0\)\
\-\ median\\:\\ 0\\.056107275582584853\ \(0\)\
\-\ posterior\\:\\ 0\\.0560683828412632\ \(0\)\
\-\ left\\:\\ 0\\.055480069284577826\ \(0\)\
\-\ consideration\\:\\ 0\\.054696715870020854\ \(0\)\
\-\ females\\:\\ 0\\.05453425314145186\ \(0\)\
\-\ according\\:\\ 0\\.05453425314145186\ \(0\)\
\-\ have\\:\\ 0\\.054165085049534926\ \(0\)\
\-\ discussed\\:\\ 0\\.05376115734675043\ \(0\)\
\-\ appeared\\:\\ 0\\.053613808066670016\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.053613808066670016\ \(0\)\
\-\ excluded\\:\\ 0\\.05332579092882382\ \(0\)\
\-\ ureter\\:\\ 0\\.053184990750774735\ \(0\)\
\-\ sites\\:\\ 0\\.05290949789085138\ \(0\)\
\-\ culture\\:\\ 0\\.05251067693290882\ \(0\)\
\-\ irregularity\\:\\ 0\\.05251067693290882\ \(0\)\
\-\ prostate\\:\\ 0\\.05251067693290882\ \(0\)\
\-\ systems\\:\\ 0\\.052381371017323174\ \(0\)\
\-\ noncontrast\\:\\ 0\\.052381371017323174\ \(0\)\
\-\ ua\\:\\ 0\\.051759983852978614\ \(0\)\
\-\ treatment\\:\\ 0\\.0516493914917173\ \(0\)\
\-\ stones\\:\\ 0\\.05117674331682638\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.05106427054630192\ \(0\)\
\-\ collecting\\:\\ 0\\.05084324109152306\ \(0\)\
\-\ observation\\:\\ 0\\.05084324109152306\ \(0\)\
\-\ analysis\\:\\ 0\\.05041603037493654\ \(0\)\
\-\ protein\\:\\ 0\\.05031216225704911\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.05031216225704911\ \(0\)\
\-\ values\\:\\ 0\\.0500072001078135\ \(0\)\
\-\ has\\:\\ 0\\.04952615820778557\ \(0\)\
\-\ which\\:\\ 0\\.04930270021755145\ \(0\)\
\-\ appreciated\\:\\ 0\\.04887670009066455\ \(0\)\
\-\ options\\:\\ 0\\.04887670009066455\ \(0\)\
\-\ contour\\:\\ 0\\.04878829165603706\ \(0\)\
\-\ squamous\\:\\ 0\\.04878829165603706\ \(0\)\
\-\ stranding\\:\\ 0\\.04852789623882536\ \(0\)\
\-\ invasion\\:\\ 0\\.04835818033262554\ \(0\)\
\-\ gross\\:\\ 0\\.04810915722524081\ \(0\)\
\-\ hematuria\\:\\ 0\\.04794669449667182\ \(0\)\
\-\ infections\\:\\ 0\\.04786649285456845\ \(0\)\
\-\ felt\\:\\ 0\\.047629870552668485\ \(0\)\
\-\ flank\\:\\ 0\\.04755228776927234\ \(0\)\
\-\ complaint\\:\\ 0\\.04695342271925786\ \(0\)\
\-\ afebrile\\:\\ 0\\.04680942241608003\ \(0\)\
\-\ thought\\:\\ 0\\.04680942241608003\ \(0\)\
\-\ 65\\:\\ 0\\.046390067410131235\ \(0\)\
\-\ evaluated\\:\\ 0\\.04632193924607133\ \(0\)\
\-\ by\\:\\ 0\\.04604426615720841\ \(0\)\
\-\ hemangioma\\:\\ 0\\.04560309350047294\ \(0\)\
\-\ count\\:\\ 0\\.044760429632740406\ \(0\)\
\-\ growth\\:\\ 0\\.044703004453867566\ \(0\)\
\-\ young\\:\\ 0\\.044703004453867566\ \(0\)\
\-\ pathologic\\:\\ 0\\.04442097075529071\ \(0\)\
\-\ room\\:\\ 0\\.044365554632167535\ \(0\)\
\-\ addition\\:\\ 0\\.04388083460745767\ \(0\)\
\-\ mildly\\:\\ 0\\.043776395774170675\ \(0\)\
\-\ inflammation\\:\\ 0\\.04357089937495528\ \(0\)\
\-\ general\\:\\ 0\\.043520212117802735\ \(0\)\
\-\ caused\\:\\ 0\\.043469793759830774\ \(0\)\
\-\ amount\\:\\ 0\\.043369752434098276\ \(0\)\
\-\ limited\\:\\ 0\\.04327075322445427\ \(0\)\
\-\ from\\:\\ 0\\.043062489239961504\ \(0\)\
\-\ rule\\:\\ 0\\.04302767505871541\ \(0\)\
\-\ not\\:\\ 0\\.04280428276896461\ \(0\)\
\-\ occurs\\:\\ 0\\.04274395732749688\ \(0\)\
\-\ irregular\\:\\ 0\\.0418551008057641\ \(0\)\
\-\ an\\:\\ 0\\.04146200690484637\ \(0\)\
\-\ history\\:\\ 0\\.041425277083993406\ \(0\)\
\-\ ct\\:\\ 0\\.04127906346781013\ \(0\)\
\-\ rare\\:\\ 0\\.04092617394711863\ \(0\)\
\-\ 13\\:\\ 0\\.04088777454866411\ \(0\)\
\-\ emergency\\:\\ 0\\.040221863771299986\ \(0\)\
\-\ course\\:\\ 0\\.04004487842965925\ \(0\)\
\-\ calcifications\\:\\ 0\\.03956616668453566\ \(0\)\
\-\ laboratory\\:\\ 0\\.039368162893808206\ \(0\)\
\-\ based\\:\\ 0\\.03927068677584005\ \(0\)\
\-\ involvement\\:\\ 0\\.03923841564741896\ \(0\)\
\-\ did\\:\\ 0\\.03889048254899908\ \(0\)\
\-\ dilated\\:\\ 0\\.038828568074724686\ \(0\)\
\-\ pain\\:\\ 0\\.03879906423888578\ \(0\)\
\-\ muscle\\:\\ 0\\.038495065849421355\ \(0\)\
\-\ typically\\:\\ 0\\.03805836552826369\ \(0\)\
\-\ obstruction\\:\\ 0\\.0379733828023547\ \(0\)\
\-\ pelvis\\:\\ 0\\.037917146909347686\ \(0\)\
\-\ 50\\:\\ 0\\.03786124181762469\ \(0\)\
\-\ being\\:\\ 0\\.03777799598738749\ \(0\)\
\-\ presentation\\:\\ 0\\.037319565988262124\ \(0\)\
\-\ given\\:\\ 0\\.037293275962677626\ \(0\)\
\-\ elevated\\:\\ 0\\.036957963310054145\ \(0\)\
\-\ thickening\\:\\ 0\\.03688223511505073\ \(0\)\
\-\ less\\:\\ 0\\.03688223511505073\ \(0\)\
\-\ cases\\:\\ 0\\.03646414635894571\ \(0\)\
\-\ along\\:\\ 0\\.03632086970286155\ \(0\)\
\-\ study\\:\\ 0\\.03615639868271684\ \(0\)\
\-\ cancer\\:\\ 0\\.03610992505373724\ \(0\)\
\-\ radiation\\:\\ 0\\.03592627029168682\ \(0\)\
\-\ white\\:\\ 0\\.03576843305226902\ \(0\)\
\-\ out\\:\\ 0\\.03563519949380487\ \(0\)\
\-\ further\\:\\ 0\\.03531006499786687\ \(0\)\
\-\ no\\:\\ 0\\.035259129749132666\ \(0\)\
\-\ will\\:\\ 0\\.034893163149273904\ \(0\)\
\-\ such\\:\\ 0\\.034872790497982024\ \(0\)\
\-\ approximately\\:\\ 0\\.03459206600737543\ \(0\)\
\-\ age\\:\\ 0\\.03403567847824403\ \(0\)\
\-\ treated\\:\\ 0\\.033760185618320664\ \(0\)\
\-\ renal\\:\\ 0\\.033760185618320664\ \(0\)\
\-\ fat\\:\\ 0\\.033724049307908364\ \(0\)\
\-\ negative\\:\\ 0\\.03356311499448369\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0333180669172053\ \(0\)\
\-\ years\\:\\ 0\\.03323205874479246\ \(0\)\
\-\ abdomen\\:\\ 0\\.03307917869452488\ \(0\)\
\-\ evaluation\\:\\ 0\\.033062342838592634\ \(0\)\
\-\ for\\:\\ 0\\.032863301251427224\ \(0\)\
\-\ appearance\\:\\ 0\\.03268312813106001\ \(0\)\
\-\ through\\:\\ 0\\.032271916248039684\ \(0\)\
\-\ include\\:\\ 0\\.03225645027523943\ \(0\)\
\-\ secondary\\:\\ 0\\.03213362028521049\ \(0\)\
\-\ he\\:\\ 0\\.03210315923929909\ \(0\)\
\-\ performed\\:\\ 0\\.03207279551318901\ \(0\)\
\-\ presented\\:\\ 0\\.0316141555768164\ \(0\)\
\-\ cyst\\:\\ 0\\.031273683172844645\ \(0\)\
\-\ enhancement\\:\\ 0\\.031204261109682357\ \(0\)\
\-\ mild\\:\\ 0\\.03073200734348208\ \(0\)\
\-\ patients\\:\\ 0\\.030497974878510224\ \(0\)\
\-\ over\\:\\ 0\\.030145006633912497\ \(0\)\
\-\ abdominal\\:\\ 0\\.02965071976571388\ \(0\)\
\-\ consistent\\:\\ 0\\.029395723444679157\ \(0\)\
\-\ acute\\:\\ 0\\.029327350213170688\ \(0\)\
\-\ follow\\:\\ 0\\.029225703916027072\ \(0\)\
\-\ surgery\\:\\ 0\\.02914739050372178\ \(0\)\
\-\ bilateral\\:\\ 0\\.029136255366902102\ \(0\)\
\-\ soft\\:\\ 0\\.028862034433933047\ \(0\)\
\-\ imaging\\:\\ 0\\.028490950668476085\ \(0\)\
\-\ can\\:\\ 0\\.02844944912572123\ \(0\)\
\-\ tissue\\:\\ 0\\.028439101995479357\ \(0\)\
\-\ demonstrate\\:\\ 0\\.02818401856233168\ \(0\)\
\-\ other\\:\\ 0\\.02815386357715447\ \(0\)\
\-\ were\\:\\ 0\\.027945415950331464\ \(0\)\
\-\ demonstrates\\:\\ 0\\.027236198034569847\ \(0\)\
\-\ case\\:\\ 0\\.027236198034569847\ \(0\)\
\-\ large\\:\\ 0\\.02716358000647155\ \(0\)\
\-\ up\\:\\ 0\\.026817301918468723\ \(0\)\
\-\ findings\\:\\ 0\\.026756463240368733\ \(0\)\
\-\ female\\:\\ 0\\.02616044235378864\ \(0\)\
\-\ within\\:\\ 0\\.024968997736406272\ \(0\)\
\-\ that\\:\\ 0\\.023526561260002313\ \(0\)\
\-\ as\\:\\ 0\\.021779427159335146\ \(0\)\
\-\ there\\:\\ 0\\.021571324123506867\ \(0\)\
\-\ are\\:\\ 0\\.020571501105630836\ \(0\)\
\-\ old\\:\\ 0\\.016044971360018024\ \(0\)\
